Journal Supplement: A Contemporary Landscape of the Clinical and Biological Research in Neurofibromatosis Type 1
Upon completion of this activity, participants should be better able to: Describe the relevance of the RAS/MAPK signaling pathway in the pathogenesis of NF1 and the mechanism of action of MEK inhibitors, Interpret efficacy and safety data from the latest clinical trials investigating MEK inhibitors, Describe the molecular drivers for the spectrum of tumors in NF1, Assess the development of potential targeted therapies for the spectrum of tumors in NF1, and Describe the importance of developing new measures of quality of life to facilitate the design of clinical trials in NF1.
This activity is designated for 4.0 AMA PRA Category 1 Credits™.
To access this supplement to Neuro-Oncology Advances, click here.
On-Demand Webinar: Will MEK Inhibitors Change the Future Paradigm of Neurofibromatosis Type 1
The goal of this activity is to improve knowledge related to mitogen-extracellular activated protein kinase kinase (MEK) inhibitors and their role in the treatment of neurofibromatosis type 1 (NF1)-related tumors. The facutly for this education are David H. Gutmann, Washington University School of Medicine, and Roger J. Packer, Children’s National Hospital. This activity is designated for .5 AMA PRA Category 1 Credits™.
To access this content, click here
. You will be asked to create an account on the MedScape website.